TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and LASP1 to modulate the sensitivity of HCC cells to TKIs

• Published in: Cell death & disease 2023-01, Vol.14 (1), p.47-47, Article 47
• Main Authors: Yang, Chong, Jin, Xin, Liu, Xingchao, Wu, Gang, Yang, Wenhao, Pang, Beichuan, Jiang, Jipeng, Liao, Dongxu, Zhang, Yu
• Format: Article
• Language: English
• Subjects: 13/1; 13/2; 13/31; 13/51; 13/89; 13/95; 631/67/1059; 631/67/395; Adaptor Proteins, Signal Transducing - genetics; AKT protein; Antibodies; Biochemistry; Biomedical and Life Sciences; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - pathology; Carrier Proteins; Cell Biology; Cell Culture; Cell Line, Tumor; Cytoskeletal Proteins; Forkhead Box Protein O1 - genetics; FOXO1 protein; Hepatocellular carcinoma; Hepatocytes; Humans; Immunology; Life Sciences; LIM Domain Proteins; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - pathology; Metastases; Nuclear transport; Phosphorylation; Protein-tyrosine kinase; Proto-Oncogene Proteins c-akt; Ubiquitin-protein ligase
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-023-05577-7

For patients with advanced or metastatic Hepatocellular carcinoma (HCC) who are not suitable for surgical resection, systemic therapy has been considered to be the standard treatment. In recent years, a small subset of patients with unresectable HCC have been benefit from tyrosine kinase inhibitors (TKIs), and the overall survival time of these patients is significantly increased. However, all responders ultimately develop resistance to TKI treatment. The tripartite motif (TRIM) family member TRIM15 acts as an E3 ligase to mediate the polyubiquitination of substrates in cells. However, the biological role of TRIM15 in HCC is still an enigma. In our study, our results demonstrated that TRIM15 was abnormally upregulated in liver cancer cells after treated with TKIs and that this upregulation of TRIM15 contributed to TKI resistance in liver cancer cells. Then, we demonstrated that the upregulation of TRIM15 after TKI treatment was mediated by the AKT/FOXO1 axis. Moreover, we demonstrated that TRIM15 induced the nuclear translocation of LASP1 by mediating its K63-linked polyubiquitination, which modulated sensitivity to TKIs by increasing the phosphorylation of AKT and the expression of Snail in liver cancer cells. Collectively, we identified a novel AKT/FOXO1/TRIM15/LASP1 loop in cells, which provided potential candidates for overcoming TKI resistance in HCC.